Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cell body

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,412 result(s) found for: Cell body. Displaying page 64 of 71.
    «« First « Previous 60  61  62  63  64  65  66  67  68  Next» Last»»
    EudraCT Number: 2020-003494-22 Sponsor Protocol Number: ANB019-207 Start Date*: 2021-02-24
    Sponsor Name:AnaptysBio Inc.
    Full Title: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ANB019 in the Treatment of Acneiform Rash in Subjects with Cancer Receiving EGFRi or MEKi Therapy
    Medical condition: Acneiform Rash
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004858 10037847 Rash acneiform LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Prematurely Ended) CZ (Prematurely Ended) LV (Prematurely Ended) BG (Prematurely Ended) HU (Completed)
    Trial results: View results
    EudraCT Number: 2019-004034-42 Sponsor Protocol Number: CA41705 Start Date*: 2020-08-31
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OBINUTUZUMAB IN PATIENTS WITH ISN/RPS 2003 CLASS III OR IV LUPUS NEPHRITIS
    Medical condition: lupus nephritis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10025140 Lupus nephritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) PL (Trial now transitioned) FR (Trial now transitioned) GB (GB - no longer in EU/EEA) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-005189-75 Sponsor Protocol Number: BO39633 Start Date*: 2017-07-13
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: AN OPEN-LABEL, MULTICENTER EXTENSION AND LONG-TERM OBSERVATIONAL STUDY IN PATIENTS PREVIOUSLY ENROLLED IN A GENENTECH- AND/OR F. HOFFMANN LA ROCHE LTD-SPONSORED ATEZOLIZUMAB STUDY
    Medical condition: Cancer (Future parent protocols may include other cancer that are not included in this section)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10046721 Urothelial carcinoma bladder stage III LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029514 Non-small cell lung cancer NOS LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10023400 Kidney cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Trial now transitioned) GB (GB - no longer in EU/EEA) ES (Ongoing) PL (Trial now transitioned) BE (Completed) FR (Trial now transitioned) NL (Ongoing) SI (Completed) PT (Completed) DE (Completed) LV (Prematurely Ended) LT (Ongoing) SK (Prematurely Ended) BG (Completed) IT (Completed) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-004572-30 Sponsor Protocol Number: GS-US-406-1840 Start Date*: 2016-03-31
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Entospletinib, a Selective SYK Inhibitor, in Combination with Systemic Corticosteroids as Fi...
    Medical condition: Chronic Graft Versus Host Disease (cGVHD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10066261 Chronic graft versus host disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) ES (Prematurely Ended) FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-004423-36 Sponsor Protocol Number: PTG-300-03 Start Date*: 2019-04-08
    Sponsor Name:Protagonist Therapeutics, Inc.
    Full Title: An Open Label Extension Study of PTG-300 in Non-Transfusion Dependent (NTD) and Transfusion-Dependent (TD) β-thalassemia Subjects
    Medical condition: β-Thalassemia Subjects with Chronic Anemia (transfusion and non transfusion dependent)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10043391 Thalassaemia beta PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GR (Completed) GB (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-020807-57 Sponsor Protocol Number: CINC424B2301 Start Date*: 2011-02-08
    Sponsor Name:Novartis Pharma Services AG
    Full Title: Randomized, open label, multicenter phase III study of Efficacy and Safety in Polycythemia vera subjects who are resistant to or intolerant of hydroxyurea: JAK iNhibitor INC424 tablets verSus bEst ...
    Medical condition: Polycythemia vera
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004864 10036061 Polycythemia vera LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) ES (Completed) GB (Completed) IT (Completed) NL (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2015-005704-29 Sponsor Protocol Number: LUNG-NEPA Start Date*: 2016-06-08
    Sponsor Name:CONSORZIO ONCOTECH
    Full Title: A standard regimen of dexamethasone in comparison to two dex-sparing regimens in addition to NEPA in preventing CINV in na¿ve NSCLC patients to be treated with cisplatin based chemotherapy: a three...
    Medical condition: Chemotherapy-Induced Nausea and Vomiting (CINV) in non-small cell lung cancer (NSCLC) patients receiving a cisplatin-based chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10008443 Chemotherapy antiemetic prophylaxsis LLT
    21.1 10042613 - Surgical and medical procedures 10054133 Prophylaxis of nausea and vomiting PT
    21.1 10042613 - Surgical and medical procedures 10008448 Chemotherapy induced emesis prophylaxis LLT
    21.1 10042613 - Surgical and medical procedures 10049091 Chemotherapy antiemetic prophylaxis LLT
    21.1 10042613 - Surgical and medical procedures 10036899 Prophylaxis against chemotherapy induced vomiting LLT
    21.1 10042613 - Surgical and medical procedures 10008449 Chemotherapy inducted emesis prophylaxis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-004195-30 Sponsor Protocol Number: ABX464-004 Start Date*: 2016-05-24
    Sponsor Name:Abivax
    Full Title: A multi-center, randomized, double-blind, placebo-controlled Phase IIa trial to compare the safety of ABX464 given at a fixed dose to placebo in fully controlled HIV infected patients treated with ...
    Medical condition: Human Immunodeficiency Virus (HIV)
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004862 10020443 Human immunodeficiency virus syndrome LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) ES (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2018-000468-27 Sponsor Protocol Number: BVX-010 Start Date*: 2018-07-04
    Sponsor Name:BiondVax Pharmaceuticals Ltd.
    Full Title: A pivotal, multicentre, randomized, modified double-blind, placebo-controlled phase 3 trial to assess the safety and clinical efficacy of M-001, an influenza vaccine administered intramuscularly tw...
    Medical condition: Flu vaccination
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10016794 Flu vaccination LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) PL (Completed) LV (Completed) BG (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2018-000096-32 Sponsor Protocol Number: METRO-PD1-1708 Start Date*: 2018-11-15
    Sponsor Name:Centre Oscar Lambret
    Full Title: Metro-PD1: a phase I/II trial evaluating anti-PD1 (Nivolumab) in combination with metronomic chemotherapy in children and teenagers with refractory /relapsing solid tumors or lymphoma
    Medical condition: Progressive or refractory : • high grade glioma • neuroblastoma • other cerebral tumors • lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018338 Glioma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029260 Neuroblastoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006153 Brain tumor LLT
    20.0 10005329 - Blood and lymphatic system disorders 10025323 Lymphomas NEC HLGT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) BE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-000294-39 Sponsor Protocol Number: INCB18424-363 Start Date*: 2014-07-16
    Sponsor Name:Incyte Corporation
    Full Title: A Randomized, Double-Blind, Phase 3 Study of the JAK1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who ...
    Medical condition: Advanced or metastatic adenocarcinoma of the pancreas in patients that have failed or are intolerant to first-line chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10033607 Pancreatic cancer recurrent LLT
    17.1 100000004864 10033606 Pancreatic cancer non-resectable LLT
    17.1 100000004864 10033605 Pancreatic cancer metastatic LLT
    17.1 100000004864 10033604 Pancreatic cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) AT (Prematurely Ended) DK (Completed) PT (Prematurely Ended) NL (Prematurely Ended) FR (Prematurely Ended) IE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-004986-38 Sponsor Protocol Number: 337HNAS20011 Start Date*: 2022-01-04
    Sponsor Name:Inventiva S.A.
    Full Title: A randomised, double-blind, placebo-controlled, multicentre, Phase 3 study evaluating long-term efficacy and safety of lanifibranor in adult patients with non-cirrhotic non-alcoholic steatohepatiti...
    Medical condition: Non-alcoholic Steatohepatitis (NASH)
    Disease: Version SOC Term Classification Code Term Level
    22.0 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) AT (Completed) HU (Trial now transitioned) BG (Trial now transitioned) IT (Trial now transitioned) NL (Trial now transitioned) PL (Trial now transitioned) BE (Trial now transitioned) PT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-001647-39 Sponsor Protocol Number: 201585 Start Date*: 2016-10-20
    Sponsor Name:ViiV Healthcare, S.L.
    Full Title: A Phase III, randomized, multicenter, parallel-group, noninferiority, open-label study evaluating the efficacy, safety, and tolerability of switching to long-acting cabotegravir plus longacting ril...
    Medical condition: Human Immunodeficiency Virus type 1 (HIV-1)
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004862 10003582 Asymptomatic human immunodeficiency virus type I infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) SE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-002486-39 Sponsor Protocol Number: A0081128 Start Date*: 2006-11-01
    Sponsor Name:Pfizer Ltd, Ramsgate Road Sandwich, UK
    Full Title: A RANDOMIZED PLACEBO-CONTROLLED TRIAL OF THE EFFICACY AND TOLERABILITY OF FLEXIBLY DOSED PREGABALIN IN THE TREATMENT OF CANCER-INDUCED BONE PAIN.
    Medical condition: Treatment of moderate to severe chronic bone pain related to metastatic cancer.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10049038 Metastatic bone pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) DK (Prematurely Ended) FI (Completed) IT (Prematurely Ended) FR (Completed) HU (Prematurely Ended) CZ (Prematurely Ended) EE (Prematurely Ended) BG (Prematurely Ended) ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-001445-40 Sponsor Protocol Number: GreenGeneF_P3 Start Date*: 2013-01-09
    Sponsor Name:Green Cross Corporation
    Full Title: Determination of Safety, Efficacy, and Pharmacokinetics of GreenGene™ F in Previously Treated Patients 12 years of age or older Diagnosed with Severe Hemophilia A
    Medical condition: Haemophilia A
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004850 10018937 Haemophilia A LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) PL (Prematurely Ended) HR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-000126-22 Sponsor Protocol Number: A18116378 Start Date*: 2012-07-24
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: A Single Blind (Sponsor-unblinded), Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of GSK1070806 in the Treatment of Obese Subjects with T2DM.
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2005-000213-35 Sponsor Protocol Number: 20020402 Start Date*: 2005-08-05
    Sponsor Name:Swedish Orphan Biovitrum AB (publ.)
    Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Weekly Doses of Palifermin (Recombinant Human Keratinocyte Growth Factor, rHuKGF) for the Reduct...
    Medical condition: Oral mucositis
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004856 10028130 Mucositis oral LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed) AT (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-002482-19 Sponsor Protocol Number: 13EU/FSH01 Start Date*: 2013-12-12
    Sponsor Name:IBSA Institut Biochimique S.A.
    Full Title: Randomised clinical trial comparing highly purified FSH formulation (Fostimon®) and recombinant FSH (Gonal-F®) in GnRH-antagonist controlled ovarian hyperstimulation cycles.
    Medical condition: female infertility
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004872 10016398 Female infertility LLT
    Population Age: Adults Gender: Female
    Trial protocol: IT (Completed) GB (Completed) ES (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2012-005563-27 Sponsor Protocol Number: VTI-208 Start Date*: 2013-07-26
    Sponsor Name:Vital Therapies, Inc.
    Full Title: A RANDOMIZED, OPEN-LABEL, MULTICENTER, CONTROLLED STUDY TO ASSESS SAFETY AND EFFICACY OF ELAD IN SUBJECTS WITH ALCOHOL-INDUCED LIVER DECOMPENSATION (AILD)
    Medical condition: Alcohol-induced liver decompensation (AILD)
    Disease: Version SOC Term Classification Code Term Level
    17.0 10019805 - Hepatobiliary disorders 10019755 Hepatitis chronic active PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2019-003333-42 Sponsor Protocol Number: EZH-302 Start Date*: 2020-11-09
    Sponsor Name:Epizyme, Inc.
    Full Title: A Phase 1b/3 double-blind, randomized, active-controlled, 3-stage, biomarker adaptive study of tazemetostat or placebo in combination with lenalidomide plus rituximab in subjects with relapsed/refr...
    Medical condition: Relapsed/refractory follicular lymphoma
    Disease: Version SOC Term Classification Code Term Level
    24.0 10016903 - Follicle centre lymphomas, follicular grade I, II, III 10016903 Follicle centre lymphomas, follicular grade I, II, III HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Trial now transitioned) FR (Trial now transitioned) BE (Trial now transitioned) DE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 60  61  62  63  64  65  66  67  68  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Jun 12 14:58:25 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA